WO2009025743A3 - Use of trail compositions as antiviral agents - Google Patents

Use of trail compositions as antiviral agents Download PDF

Info

Publication number
WO2009025743A3
WO2009025743A3 PCT/US2008/009666 US2008009666W WO2009025743A3 WO 2009025743 A3 WO2009025743 A3 WO 2009025743A3 US 2008009666 W US2008009666 W US 2008009666W WO 2009025743 A3 WO2009025743 A3 WO 2009025743A3
Authority
WO
WIPO (PCT)
Prior art keywords
trail
cells
virus
dengue
human
Prior art date
Application number
PCT/US2008/009666
Other languages
French (fr)
Other versions
WO2009025743A2 (en
Inventor
Irene Bosch
Rajas V. Warke
Katherine J. Martin
Original Assignee
University Of Massachusetts Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusetts Medical School filed Critical University Of Massachusetts Medical School
Publication of WO2009025743A2 publication Critical patent/WO2009025743A2/en
Publication of WO2009025743A3 publication Critical patent/WO2009025743A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dengue fever is an important tropical illness for which there is currently no virus-specific treatment. Common gene expression changes, using Affymetrix GeneChips (HG-Ul 33A), were seen using several types of infected primary human cells (human umbilical vein endothelial cells (HUVECs), dendritic cells (DCs), monocytes and B cells). Tissue necrosis factor-related apoptosis inducing ligand (TRAIL), one of the common response genes, may provide additional immune modulator functions present in virus infected cells, and additional interactions between type-I and II IFN response genes and TRAIL that will increase the innate immunity to the virus or even to other pathogens like bacteria.. Dengue virus induces TRAIL expression in immune cells and HUVECs at the mRNA and protein level and was found to be dependent on an intact IFN type I signaling pathway. Anti-TRAIL antibody incubation with primary cells showed an increase in DV accumulation and conversely, a decrease in DV RNA was seen in presence of recombinant TRAIL (i.e., for example, human rTRAIL). These data suggest that TRAIL may play a role in the anti-viral response to DV infection and is a candidate for anti-viral interventions against DV. Further, TRAIL antiviral function does not promote apoptosis. The role of exogenous TRAIL in dendritic cells confirmed a strong anti-inflammatory response due to the lowering of production of mediators of inflammation present in dengue infection.
PCT/US2008/009666 2007-08-17 2008-08-13 Use of trail compositions as antiviral agents WO2009025743A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96517307P 2007-08-17 2007-08-17
US60/965,173 2007-08-17

Publications (2)

Publication Number Publication Date
WO2009025743A2 WO2009025743A2 (en) 2009-02-26
WO2009025743A3 true WO2009025743A3 (en) 2010-04-22

Family

ID=40378863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009666 WO2009025743A2 (en) 2007-08-17 2008-08-13 Use of trail compositions as antiviral agents

Country Status (1)

Country Link
WO (1) WO2009025743A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011132086A2 (en) 2010-04-21 2011-10-27 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
EP2812700B1 (en) 2012-02-09 2018-04-18 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
ES2828642T3 (en) 2013-06-25 2021-05-27 Walter & Eliza Hall Inst Medical Res Smac mimics for the treatment of persistent intracellular HBV infection
JP6661607B2 (en) 2014-08-14 2020-03-11 メメド ダイアグノスティクス リミテッド Computer analysis of biological data using manifolds and hyperplanes
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
CN109661578B (en) 2016-07-10 2022-05-10 米密德诊断学有限公司 Protein characterization for differentiating bacterial and viral infections
KR101739703B1 (en) * 2016-09-13 2017-05-24 (주) 어드밴스드 엔티 The method of diagnosing encephalitis and the apparatus thereof based on TRAIL measurement
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN116970562B (en) * 2023-09-22 2024-01-02 北京翊博生物集团有限公司 Preparation method of antigen-specific T cells and application of antigen-specific T cells in immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US20050059578A1 (en) * 2002-07-15 2005-03-17 Thorpe Philip E. Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
US20070254934A1 (en) * 2006-03-02 2007-11-01 Hruby Dennis E Antiviral drugs for treatment of arenavirus infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US20050059578A1 (en) * 2002-07-15 2005-03-17 Thorpe Philip E. Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
US20070254934A1 (en) * 2006-03-02 2007-11-01 Hruby Dennis E Antiviral drugs for treatment of arenavirus infection

Also Published As

Publication number Publication date
WO2009025743A2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2009025743A3 (en) Use of trail compositions as antiviral agents
Perera et al. The role of the unfolded protein response in dengue virus pathogenesis
da Conceição et al. Essential role of RIG-I in the activation of endothelial cells by dengue virus
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
WO2007098267A3 (en) Pseudoinfectious flavivirus and uses thereof
WO2010107739A3 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2009060429A3 (en) Compositions for conferring tolerance to viral disease in social insects, and the use thereof
BRPI0514176A (en) hcv replication inhibitors
EA201000085A1 (en) dsPHK INTRODUCED FOR THE TREATMENT OF VIRAL INFECTION
Ashfaq et al. Medicinal plants against hepatitis C virus
WO2008024763A3 (en) Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
Meng et al. EPSTI1 is involved in IL-28A-mediated inhibition of HCV infection
Mansfield et al. Transcriptional upregulation of SOCS 1 and suppressors of cytokine signaling 3 mRNA in the absence of suppressors of cytokine signaling 2 mRNA after infection with West Nile virus or tick-borne encephalitis virus
Saghazadeh et al. Implications of Toll-like receptors in Ebola infection
Shi et al. MxA is a positive regulator of type I IFN signaling in HCV infection
WO2011150320A3 (en) Activators of innate immunity
Wei et al. The role of influenza A virus-induced hypercytokinemia
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection
Zhang et al. Immune mechanisms of group B coxsackievirus induced viral myocarditis
Guerrero et al. Comparative assessment of the replication efficiency of dengue, yellow fever, and chikungunya arboviruses in some insect and mammalian cell lines
GT200600512A (en) ENZYMES TO REDUCE IMMUNE STRESS
Justina et al. COVID-19 and hypertension: Is there a role for dsRNA and activation of Toll-like receptor 3?
EA200401362A1 (en) ANTI-VIRUS THERAPY, BASED ON THE RESISTANCE OF RNA
Zhong et al. Potential clinical treatment for Ebola pandemic
CN102349995A (en) Broad-spectrum antiviral medicament as well as preparation method and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795271

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08795271

Country of ref document: EP

Kind code of ref document: A2